Literature DB >> 30995132

LncRNA NKILA Inhibits Retinoblastoma by Downregulating lncRNA XIST.

Xueman Lyu1, Yunqing Ma2, Fei Wu3, Ling Wang1, Lina Wang1.   

Abstract

Purpose: Although retinoblastoma is rare but can be deadly in some severe cases. To find novel therapeutic targets for retinoblastoma, we explored the potential role of lncRNA NKILA in retinoblastoma.
Results: We found that, comparing to healthy controls, NKILA was downregulated, while lncRNA XIST was upregulated in plasma of retinoblastoma patients and they were inversely correlated. Downregulation of NKILA distinguished early-stage patients from healthy controls. Overexpression of lncRNA NKILA mediated the downregulation of XIST in retinoblastoma cells, while XIST overexpression failed to significantly affect NKILA. Overexpression of NKILA resulted in decreased, while XIST overexpression resulted in increased proliferation, migration and invasion rates of retinoblastoma cells. In addition, rescue experiment showed that XIST overexpression attenuated the effects of NKILA overexpression on cancer cell behaviors. Conclusions: Therefore, NKILA inhibits retinoblastoma possibly by downregulating XIST, but the causality has not been fully validated.

Entities:  

Keywords:  NKILA; Retinoblastoma; XIST; cell; tumor suppressor

Year:  2019        PMID: 30995132     DOI: 10.1080/02713683.2019.1606253

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  10 in total

1.  NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas.

Authors:  Zheng Chen; Shiting Li; Lin Shen; Xiangyu Wei; Hanshuo Zhu; Xueyi Wang; Min Yang; Xuesheng Zheng
Journal:  Cell Death Dis       Date:  2020-05-07       Impact factor: 8.469

2.  LncRNA NKILA Promotes Epithelial-Mesenchymal Transition of Liver Cancer Cells by Targeting miR-485-5p.

Authors:  Yuxu Wang; Chao Li; Yuyi Shi; Jing Kuai
Journal:  J Oncol       Date:  2021-09-03       Impact factor: 4.375

Review 3.  Long non-coding RNA XIST: a novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

4.  Long intergenic non-protein coding RNA 115 (LINC00115) aggravates retinoblastoma progression by targeting microRNA miR-489-3p that downregulates 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2).

Authors:  Fang Ji; Chunhua Dai; Meng Xin; Jing Zhang; Yuru Zhang; Shu Liu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 5.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

Review 6.  Biological Function of Long Non-coding RNA (LncRNA) Xist.

Authors:  Wenlun Wang; Lu Min; Xinyuan Qiu; Xiaomin Wu; Chuanyang Liu; Jiaxin Ma; Dongyi Zhang; Lingyun Zhu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

7.  Long noncoding RNA SNHG14 promotes the aggressiveness of retinoblastoma by sponging microRNA‑124 and thereby upregulating STAT3.

Authors:  Xiaowen Sun; Hui Shen; Shubin Liu; Jing Gao; Shuyan Zhang
Journal:  Int J Mol Med       Date:  2020-03-20       Impact factor: 4.101

8.  Long Non-Coding RNA NKILA Reduces Oral Squamous Cell Carcinoma Development Through the NF-KappaB Signaling Pathway.

Authors:  Daoyong Hu; Tian Zhong; Qun Dai
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Long noncoding RNA UCA1 facilitates cell proliferation and inhibits apoptosis in retinoblastoma by activating the PI3K/Akt pathway.

Authors:  Zhongfang Yuan; Zhaona Li
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

10.  Long Non-Coding RNA TP53TG1 Upregulates SHCBP1 to Promote Retinoblastoma Progression by Sponging miR-33b.

Authors:  Hongyi Wang; Zhen Zhang; Yue Zhang; Shihai Liu; Li Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.